LAUSR

e12567Background: Eribulin is licensed for the ≥2-line treatment of patients with metastatic breast cancer. We assessed outcome of eribulin treatment in real world patients. Methods: We conducted a retrospective analysis of consecutive patients treated with eribulin for metastatic breast cancer at Guys Cancer Centre and affiliated units in South East London between Oct 2011 and Nov 2016. All data was extracted from electronic patient records. Results: We identified 158 patients with a median age of 55.8 years (range 30-94). Median WHO performance status (PS) was 1 (0-4). 68% were of white ethnicity, 23% black and 5% other. 67% were ER+, 13% Her2+ and 26% triple negative breast cancer (TNBC). 96% had visceral disease and 15% of patients had CNS involvement. Eribulin was given in 1% of patients as 1st line, 10% as 2nd, 51% as 3rd, 21% as 4th and 17% as 5thline treatment or beyond. Patients received a median of 4 cycles of eribulin (range 1-35). Median overall survival (OS) was 9.3 months and progression fre...